Dose Optimization of Inotuzumab Ozogamicin in Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia

被引：0

作者：

Deangelo, Daniel J. ^{[1
]}

Chen, Ying ^{[2
]}

Cassaday, Ryan D. ^{[3
,4
]}

Hibma, Jennifer ^{[2
]}

Yang, Derek Z. ^{[2
]}

Garrett, May ^{[2
]}

Zhang, Fan ^{[5
]}

Dimitrov, Svetoslav H. ^{[6
]}

Vandendries, Erik ^{[7
]}

Kantarjian, Hagop M. ^{[8
]}

机构：

[1] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA USA

[2] Pfizer, San Diego, CA USA

[3] Univ Washington, Seattle, WA USA

[4] Fred Hutchinson Canc Ctr, Seattle, WA USA

[5] Pfizer, Shanghai, Peoples R China

[6] Pfizer, New York, NY USA

[7] Pfizer Inc, Cambridge, MA USA

[8] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX USA

来源：

BLOOD | 2024年 / 144卷

关键词：

D O I：

10.1182/blood-2024-194244

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：732 / 733

页数：2

共 50 条

[1] Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia
Bhojwani, Deepa
Sposto, Richard
Shah, Nirali N.
Rodriguez, Vilmarie
Yuan, Constance
Stetler-Stevenson, Maryalice
O'Brien, Maureen M.
McNeer, Jennifer L.
Quereshi, Amrana
Cabannes, Aurelie
Schlegel, Paul
Rossig, Claudia
Dalla-Pozza, Luciano
August, Keith
Alexander, Sarah
Bourquin, Jean-Pierre
Zwaan, Michel
Raetz, Elizabeth A.
Loh, Mignon L.
Rheingold, Susan R.
LEUKEMIA, 2019, 33 (04) : 884 - 892
[2] Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia
Deepa Bhojwani
Richard Sposto
Nirali N. Shah
Vilmarie Rodriguez
Constance Yuan
Maryalice Stetler-Stevenson
Maureen M. O’Brien
Jennifer L. McNeer
Amrana Quereshi
Aurelie Cabannes
Paul Schlegel
Claudia Rossig
Luciano Dalla-Pozza
Keith August
Sarah Alexander
Jean-Pierre Bourquin
Michel Zwaan
Elizabeth A. Raetz
Mignon L. Loh
Susan R. Rheingold
Leukemia, 2019, 33 : 884 - 892
[3] Correction: Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia
Deepa Bhojwani
Richard Sposto
Nirali N. Shah
Vilmarie Rodriguez
Constance Yuan
Maryalice Stetler-Stevenson
Maureen M. O’Brien
Jennifer L. McNeer
Amrana Quereshi
Aurelie Cabannes
Paul Schlegel
Claudia Rossig
Luciano Dalla-Pozza
Keith August
Sarah Alexander
Jean-Pierre Bourquin
Michel Zwaan
Elizabeth A. Raetz
Mignon L. Loh
Susan R. Rheingold
Leukemia, 2019, 33 : 1061 - 1062
[4] Results of the compassionate program of inotuzumab ozogamicin for adult patients with relapsed or refractory acute lymphoblastic leukemia in Spain
Torrent, Anna
Morgades, Mireia
Garcia-Calduch, Olga
de Llano, Maria Paz Queipo
Montesinos, Pau
Navarro, Irene
Hernandez-Rivas, Jesus Maria
Barez-Garcia, Abelardo
Gonzalez-Campos, Jose
Oiartzabal, Itziar
Valero, Marta
Cervera, Marta
Zudaire, Teresa
Albors-Ferreiro, Manuel
Lopez-Godino, Oriana
Gil-Cortes, Cristina
Villalon, Lucia
Saldana, Raquel
Ribera, Josep-Maria
EUROPEAN JOURNAL OF HAEMATOLOGY, 2023, 111 (03) : 485 - 490
[5] Results of the Compassionate Program of Inotuzumab Ozogamicin for Adult Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia in Spain
Ribera, Josep-Maria
Garcia, Olga
Montesinos, Pau
Rodriguez-Veiga, Rebeca
Garcia-Fortes, Maria
Barez Garcia, Abelardo
Oiartzabal, Itziar
Gonzalez-Campos, Jose A.
Mendez Sanchez, Jose Angel
Zudaire, Maite
Villalon, Lucia
Lopez-Godino, Oriana
Gil, Cristina
Vicent, Ana
Saldana, Raquel
Valero, Marta
Torrent, Anna
Maria Hernandez-Rivas, Jesus
BLOOD, 2021, 138
[6] Role of inotuzumab ozogamicin in the treatment of relapsed/refractory acute lymphoblastic leukemia
George, Binsah
Kantarjian, Hagop
Jabbour, Elias
Jain, Nitin
IMMUNOTHERAPY, 2016, 8 (02) : 135 - 143
[7] Inotuzumab ozogamicin for relapsed/refractory acute lymphoblastic leukemia: outcomes by disease burden
DeAngelo, Daniel J.
Advani, Anjali S.
Marks, David, I
Stelljes, Matthias
Liedtke, Michaela
Stock, Wendy
Goekbuget, Nicola
Jabbour, Elias
Merchant, Akil
Wang, Tao
Vandendries, Erik
Neuhof, Alexander
Kantarjian, Hagop
O'Brien, Susan
BLOOD CANCER JOURNAL, 2020, 10 (08)
[8] Inotuzumab ozogamicin is effective in relapsed/refractory extramedullary B acute lymphoblastic leukemia
Luca Bertamini
Jacopo Nanni
Giovanni Marconi
Mariachiara Abbenante
Valentina Robustelli
Francesco Bacci
Antonella Matti
Stefania Paolini
Chiara Sartor
Silvia Lo Monaco
Maria Chiara Fontana
Stefano De Polo
Michele Cavo
Antonio Curti
Giovanni Martinelli
Cristina Papayannidis
BMC Cancer, 18
[9] Inotuzumab ozogamicin for relapsed/refractory acute lymphoblastic leukemia: outcomes by disease burden
Daniel J. DeAngelo
Anjali S. Advani
David I. Marks
Matthias Stelljes
Michaela Liedtke
Wendy Stock
Nicola Gökbuget
Elias Jabbour
Akil Merchant
Tao Wang
Erik Vandendries
Alexander Neuhof
Hagop Kantarjian
Susan O’Brien
Blood Cancer Journal, 10
[10] Inotuzumab ozogamicin in the treatment of relapsed/refractory acute B cell lymphoblastic leukemia
Uy, Natalie
Nadeau, Michelle
Stahl, Maximilian
Zeidan, Amer M.
JOURNAL OF BLOOD MEDICINE, 2018, 9 : 67 - 74

← 1 2 3 4 5 →